The expression of this gene is under the fine-tuned regulation of signaling pathways such as IL-4/STAT6, and targeted interventions against its downstream signaling have been successfully applied in treating severe asthma and chronic spontaneous urticaria, affirming the pivotal value of FCER1A as a critical immune marker and therapeutic target [26,39]. The gene discussed is IL4; the disease is chronic idiopathic urticaria.